Ceftriaxone

Third generation cephalosporins are effective in treating a large variety of infections resistant to many other drugs ceftriaxone rocephin ; and and cefixime suprax ; are first-line antibiotics for treating gonorrhea.

Ism in protoplasmic streaming and ameboid movement. Int. Rev. Cytol. 34, 169-249. LAZARIDES, E. 1976 ; . Actin, a-actinin and tropomyosin interaction in the structural organization of actin filaments in non-muscle cells. J. Cell Biol. 68, 202-219. LAZARIDES, E. & WEBER, K. 1974 ; . Actin antibody: The specific visualization of actin filaments in non-muscle cells. Proc. natn. Acad. Sci. U.SA. 71, 2268-2272. NACHMIAS, V. T. 1979 ; . The contractile proteins of Physarum polycephalum and actin polymerization in plasmodial extracts. In Cell Motility. Molecules and Organization ed. S. Hatano, H. Ishikawa & S. Sato ; , pp. 33--57. Tokyo: University of Tokyo Press. NAGAI, R., YOSHIMOTO, Y. & KAMIYA, N. 1978 ; . Cyclic production of tension force in the plasmodial strand of Phvsarum polvcephalum and its relation to microfilament morphology. J. Cell Sci. 33, 205-225. For children under age 2, or patients with a frequent otitis media history, or patients with antibiotic use within 3 months, or patients who appear seriously ill, it is prudent to proceed directly to high-dose ; amoxicillin clavulanate Augmentin ES-extra strength, pediatric, or XR-extended release, adult ; , or intramuscular ceftriaxone. Pneumococcal strains with reduced susceptibility to penicillin are usually susceptible to an enhanced doubled ; amoxicillin dosage, to which can be added the clavulanate for hemophilus and M. cat. ; Infections that fail treatment with the above medications are probably due to highly penicillin-resistant multi-drug-resistant ; pneumococcal strains. Culture-directed therapy from myringotomy ; is advantageous. For high-level penicillin-resistant pneumococci: See Section III.A, page 46 ; Ceftriaxone Rocephin ; IM or IV Levo-or-moxifloxacin oral See page 15, Section I.I * Vancomycin IV with or without rifampin.

Upsher-Smith product Vandazole for bacterial vaginosis ; among last year's highlights, as well as the new business from Dey and Abbott. He was also delighted to have begun working again on Abbott's cardiovascular product Simdax, which had been reassigned for global launch in 2004. This year is shaping up nicely as Goble has added StoneBridge Pharma to its roster and recently picked up Vivitrol for client Cephalon. Looking at the first part of 2006, Kuchta says it is probably the best year he's seen in his decade at the agency. "I don't ever want to hit a slow period like we did last summer, " he says. "We're at a great point. We won something like 10 different products and assignments over the last 18 months. Our client base is a stable of long-term clients and some exciting new ones. If we have to hire some folks and keep our growth going, we'll do that. We expect the growth and are looking for how to handle the growth." Goble's staff has pretty much held steady at around 49 people, despite last year's revenue slide. "We don't do anything rash and start laying off staff. We stick with it, trusting that business will always be there." Kuchta reports no problem attracting talent, but he adds that finding the "right" people is a challenge. "We're getting floods of resumes from people who are getting let go, " Kuchta says. "People seek us out. We don't have a revolving door. If I had 300 seats to fill, I'd probably be saying something different." Not that Kuchta is looking to swell the agency that. Chloramphenicol, ciprofloxacin, rifampin, tetracycline, and vancomycin Table 1 ; . By using the staphylococcal susceptibility breakpoint for erythromycin 0.5 g ml ; , 97% of the B. anthracis isolates were categorized as intermediate. That categorization would have been changed to 100% susceptible if the breakpoint had been moved 1 dilution higher to 1 g ml. No data are available from studies with clinical or animal models to indicate which interpretation is correct. The 50 historical B. anthracis isolates were also tested for antimicrobial resistance in parallel by the Etest method Table 2 ; . For 45 of the isolates, the penicillin MICs obtained by one or both methods were less than or equal to the lowest dilution tested, limiting the number of on-scale comparisons that could be made. Off-scale values were less of a problem with the other antimicrobial agents tested. Tests were repeated for five isolates for which the MICs obtained by the broth microdilution reference method and the Etest method differed by 1 doubling dilution. These included the result for ceftriaxone for one isolate and the results for penicillin for four isolates. In general, the penicillin MICs obtained by the Etest method were lower than those obtained by the broth microdilution reference method. On initial testing, the MIC for the penicillin-resistant strain obtained by the Etest was 9 log2 dilutions lower than that and cerivastatin.

At this level, the CD4 count is taken into account to assess the likelihood of an OI. In patients with low CD4 count the pre-test probability of an OI high that this is the most probable cause of headache, even in the absence of fever. B ; Neurological evaluation: see page 256 annotation B. C ; Focal signs Hemiparesis, cranial nerve palsies, seizures, ataxia, aphasia. D ; IRIS is a possibility if a patient started recently with HAART between 1 week to 6 months ; See annotation B page 258. E ; If toxoplasmosis is a frequent problem in your region, it is justifiable to start empirical treatment against Toxoplasma gondii immediately. If you can do toxoplasma antibody tests, it may guide you in the decision to treat for toxoplasmosis or consider another diagnosis. See annotation E page 258. Treatment consists of combination therapy with sulfadiazine and pyrimethamine, or with cotrimoxazole see page 245 ; . F ; Toxoplasmosis usually responds well to treatment within 7-10 days, and this response can be used to support the diagnosis. Full dose treatment with cotrimoxazole should be maintained for 4 weeks or for 6 weeks in the case of sulfadiazine pyrimethamine. If the response is good, secondary prophylaxis is needed: cotrimoxazole 960 mg daily, or pyrimethamine 25 mg daily and sulfadiazine 2-4 g daily. This may be interrupted when the CD4 is above 100-200 cells mm in a patient on stable HAART. If there is no response after 7 days, a diagnosis of cerebral toxoplasmosis is unlikely. Check VDRL or RPR. G ; See page 250. H ; The threshold for doing an LP should be very low in patients with headache and low CD4 counts. Examination of CSF at level C includes: opening pressure normally: 7-18 cmH2O ; , cell count and cell type, glucose and protein level, Gram stain, India ink, AFB and CRAg. Normal CSF has a protein content of 15-45 mg dl, a glucose content of 45-80 mg dl, and a cell count less than 5 cells mm3 see table page 248 ; I ; Elevated WBC count in the CSF with predominant neutrophils is suggestive of bacterial meningitis. Glucose in CSF is low and protein high. Sometimes the Gram stain shows Gram-positive or Gram-negative bacteria; this will orient the choice of the antibiotic. For empirical therapy, the first choice in bacterial meningitis is ceftriaxone 2g IV 2 daily. When ceftriaxone is not available: benzylpenicillin 12-24 MIU daily by IV injections divided into 4 doses, or chloramphenicol 4 g daily by IV injection in 4 divided doses. Treat for a minimum of 7 days or for 5 days after the. Correspondence The three strains transferred resistance determinants to the E. coli recipient by conjugation. The resistance determinants of strain EP112 were transferred as a unit to all transconjugants, whereas those of AS30 and AS31 were segregated in most of the respective transconjugants. Resistance to newer cephalosporins was transferred to the majority of the latter strains. Isoelectric focusing and plasmid content analyses showed that resistance to the newer -lactams in strains AS30 and AS31 resulted from the acquisition of 10 kb plasmids that encoded -lactamases with isoelectric points pIs ; of 8.4. Determination of the nucleotide sequence of 330 bp fragments of the respective bla genes demonstrated that the enzymes closely resembled the CTX-M-2 class A ESBL. The deduced amino acid sequences 103 residues ; , aligned with CTX-M-2, spanned the C-terminal region of the enzymes. The -lactamase of strain AS30 differed from CTX-M-2 by two amino acids Cys in place of Ser228 and Val in place of Ile278 ; , thereby giving 98% homology. The enzyme produced by AS31 also differed from CTX-M-2 by two amino acid residues Met in place of Leu225 and Gly in place of Val230 ; , also giving 98% homology. By determining the DNA sequence with SHV-specific primers, the enzyme conferring a `ceftazidimase' phenotype on EP112 was shown to be an SHV-5-type lactamase identical to that frequently encountered in Enterobacteriaceae strains isolated in Greek hospitals8, 9 and encoded by a large 100 kb ; self-transmissible plasmid. The CTX-M-type -lactamases comprise a novel cluster of plasmid-mediated extended-spectrum enzymes.10 They are related to the chromosomal -lactamases of Klebsiella oxytoca and confer resistance to ceftriaxone, cefotaxime and aztreonam. The -lactamases of strains AS30 and AS31 that conferred resistance to newer -lactams are apparently CTX-M-type variants. Epidemiological data suggest that strain AS30 was acquired in Russia and the recent isolation of S. typhimurium strains producing plasmid-mediated CTX-M-type -lactamases in the St Petersburg region supports this hypothesis.6 Closely related, multiresistant plasmids mediating SHV-5-type -lactamase activities have spread to Kleb siella pneumoniae and E. coli strains isolated from patients in Greek hospitals.9 These plasmids mediate an antibiotic resistance phenotype similar to that exhibited by S. typhimurium strain EP112. The possibility that plasmids mediating TEM- or SHV-type ESBLs have been transferred to Salmonella spp. has also been suggested by other investigators.3, 5 Non-typhoid Salmonella spp. strains isolated in Greece exhibit cross-resistance to multiple antibiotics.11 Ceftriaxone has been used routinely since 1990 as empirical therapy of newborn infants with salmonellosis. The emergence of oxyimino -lactam-resistant S. typhimurium strains underscores the importance of closely monitoring trends in the patterns of resistance of this pathogen. 274 and cetuximab. As for acute urethritis in males Benzathine penicillin PLUS Azithromycin OR Erythromycin Ceftriaxone OR Azithromycin 2.4 mU IM as single dose 1 g PO stat 500 mg PO 8 hrly x 14 days 250 mg Im stat 1 g PO single dose. For the treatment of serious infections the recommended dose is 50-75mg kg in terms of ceftriaxone ; given in divided doses every 12 hours and chamomile. Objective: We examined recent trends in success rates for assisted reproduction and determined the influence of changes in patient selection and treatment characteristics on these trends. Methods: We collected baseline information and abstracted treatment-related details and outcomes on 1244 couples accepted for in vitro fertilization IVF ; or gamete intrafallopian transfer GIFT ; at three clinics in greater Boston from 1994 1998. Results: Delivery rates per initiated cycle improved significantly from 14.9% for IVF and 20.6% for GIFT in 1994 1995 to 22.5% for IVF and 28.0% for GIFT in 19971998 P .001 ; . After adjusting for female age, the two treatmentrelated variables that appeared most likely to explain this trend were decreased use of GnRH agonists in short course flare ; regimens and increased use of highly purified forms of urinary gonadotropins. Conclusion: There were significant improvements in the success rates for IVF and GIFT from 1994 1998 that correlated with changes in ovulation induction regimens. Obstet Gynecol 2000; 95: 61 by The American College of Obstetricians and Gynecologists. Lettuce The Meeting received information on trials conducted on outdoor lettuce from France and the UK and on protected lettuce in France, Italy, Spain and the UK. Lettuce types used in these trials included `Iceberg-type' head lettuce, the less compact crisphead or butterhead lettuce and leaf lettuce. Where possible, these lettuce types have been identified in the following tables. In these trials, two foliar applications of pirimicarb 50% WG formulations ; were made at 7-12 day intervals to unreplicated 10-120 square metre plots, either as broadcast or band sprays using small plot boom or knapsack hand lance or mini boom ; sprayers to obtain full foliar coverage. Plants grown in the field received the second application between 39 and 51 days after planting while those and chaparral.

A multicentre, randomised controlled, open labelled, parallel group, non-inferiority trial to compare the efficacy of oral antibiotic treatment alone with treatment started parenterally and completed orally in children with a first episode of acute pyelonephritis. A total of 502 children aged 1 month to 7 years with clinical pyelonephritis were randomised to oral coamoxiclav 50 mg kg day in three doses for 10 days ; or parenteral ceftriaxone 50 mg kg day in a single parenteral dose ; for three days, followed by oral co-amoxiclav 50 mg kg day in three divided doses for seven days ; . Primary outcome was the rate of renal scarring. Secondary measures of efficacy were time to defervescence 37C ; , reduction in inflammatory indices, and percentage with sterile urine after 72 hours. Intention to treat analysis showed no significant differences between oral n 244 ; and parenteral n 258 ; treatment, both in the primary outcome scarring scintigraphy at 12 months 27 197 13.7% ; v 36 203 17.7% ; , difference in risk 4%, 95% confidence interval 11.1% to 3.1% ; and secondary outcomes time to defervescence 36.9 hours SD 19.7 ; v 34.3 hours SD 20 ; , mean difference 2.6 0.9 to 6.0 white cell. Lamivudine: The chemical name of lamivudine is 2R, cis ; -4-amino-1- 2-hydroxymethyl-1, 3oxathiolan-5-yl ; - 1H ; -pyrimidin-2-one. Lamivudine is the - ; enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as - ; 2, 3-dideoxy, 3-thiacytidine. It has a molecular formula of C8H11N3O3S and a molecular weight of 229.3 daltons. It has the following structural formula and charcoal. Reports, nor were the susceptibility rates of the isolates to penicillin. We investigated the in vitro activity of ciprofloxacin against penicillin-susceptible and moderately penicillin-resistant strains of meningococcus to determine if the mechanism of decreased susceptibility to penicillin had any effect on the activities of ciprofloxacin and other compounds. We suspect that the mechanism of reduced susceptibility to penicillin in our isolates involves altered penicillin-binding proteins studies to prove this are ongoing ; . This finding would be consistent with the findings by other investigators for similar strains recovered in Spain 10 ; . Ciprofloxacin activity against moderately penicillin-resistant strains of N. meningitidis was slightly different from that of strains fully susceptible to penicillin Table 2 ; . This result needs to be interpreted with caution since the difference between the MICs at which 50 and 90% of the isolates were inhibited Table 1 ; was determined by using only one isolate. A larger study may help to resolve this observation. Of the two mechanisms associated with ciprofloxacin resistance altered membrane permeability and altered DNA gyrase ; we were concerned that cell wall changes may have affected the diffusion of the antimicrobial agent into the bacterial cell. The changes that have resulted in the decreased susceptibility to penicillin do not appear to have changed the diffusion of ciprofloxacin into the cell since activity against all of the strains tested does not appear to be significantly altered. Bellete et al. 1 ; reported on the susceptibility of meningococcal isolates recovered during an outbreak of meningococcal disease in Malawi. All 77 meningococcal isolates were susceptible to chloramphenicol, ciprofloxacin, and rifampin. Six isolates were resistant to penicillin and all but one was resistant to sulfonamides. Tzanakaki et al. 11 ; found that 48, 19, and 36% of meningococcal isolates from patients with meningitis, from school children, and from recruits, respectively, in Greece were not susceptible to penicillin. All but one isolate was susceptible to ciprofloxacin. Resistance to rifampin was not detected in meningococcal isolates from patients with meningitis; however, resistance was detected in 6% of the isolates recovered from carriers. Finally, Hughes et al. 3 ; evaluated the E test for susceptibility testing of N. meningitidis. Of 102 isolates tested, 84.3% were fully susceptible to penicillin, while 100% were susceptible to ciprofloxacin. The results obtained from testing cefotaxime, ceftriaxone, chloramphenicol, and rifampin were, for the most part, similar to those of other investigators. Saez-Nieto et al. 10 ; found that there was a very slight increase in the MICs of cefotaxime and ceftriaxone for penicillin-resistant N. meningitidis. In our study, there was a slight increase in the MICs of cefotaxime when tested against moderately resistant strains. It is interesting that of 11 isolates for which the penicillin MIC was 0.047 g ml, the cefotaxime MICs were 0.006 g ml for 4 isolates and 0.016 g ml for 1 isolate. For 10 of 11 isolates the ceftriaxone MIC.

Authorized by Florida Legislature in SB 838 passed on May 6, 2005. Draft waiver request posted on AHCA website August 31, 2005. Agency received a number of comments on the draft. Agency reached agreement on UPL program with Centers for Medicare and Medicaid Services CMS ; . Waiver request submitted to CMS on October 3, 2005, after 30-days posting. Waiver request approved by CMS on October 19, 2005 and chlorambucil and ceftriaxone. Acknowledgments-We thank Dr. Frank R. N. Gurd for the provision of laboratory space and equipment, and Dr. Ward w. Moore of the Medical Sciences Program for his constant interest and support. We thank Drs. W. Terry Jenkins and Richard D. England for helpful discussions throughout this work. We also thank Timothy A. Sutton for the verification of the homogeneity of the '2SI-NG and Loris D. McVittie for aiding in the preparation of the lZ5I-NG. The excellent technical assistance of Sarah Burton is gratefully acknowledged. 100 patients entered by the groups Borstkanker Onderzoeksgroup Nederland BOOG ; Gruppo italiano Malattie Ematologiche dell'adulto GiMENa ; 20 100 patients entered by the groups Swedish Breast Cancer Group SWEBCG ; Groupe d'Etudes des Lymphomes de l'adulte GELa ; anglo-Celtic Cooperative Oncology Group aCCOG ; french Sarcoma Group fSG ; Schweizerisches arbeitsgemeinschaft Klin. Krebsforschung SaKK ; federation francophone de Cancerologie digestive ffCd ; German MdS Study Group GMdS ; arbeitsgemeinschaft internistische Onkologie, Chirurgische aiO ; 20 patients entered by the groups fdration Nationale des Centres de Lutte contre le Cancer fNCLCC ; National Cancer institute of Canada-Clinical Trial Group NCiC ; Grupo Espanol de investigacion del Cancer de Ovario GEiCO ; Grupo Espanol de investigacion en sarcomas GEiS ; German Testicular Cancer Study Group GTCSG ; italian Lung Cancer project iLCp ; italian Sarcoma Group iSG ; Groupe d'Etude des Tumeurs uro-Genitales GETuG ; australasian Gastro-intestinal Trials Group aGiTG ; international Breast Cancer Study Group iBCSG ; National Cancer Research institute - Bladder Cancer Group-uK NCRiBCSG ; Grupo Germinal iT GG ; australasian Leukaemia and Lymphoma Group aLLG ; National Cancer Research inst. -Colorectal Cancer Group-uK NCRiCCSG ; Grup per l'Estudi del Limfomes de Catalunya i Balears GELCaB ; Nordic Lymphoma Group NLG ; industry and chlordiazepoxide.

[Law00] C. K. Law, I. A. Walmsley and J. H. Eberly, Continuous Frequency Entanglement: Effective Finite Hilbert Space and Entropy Control, Phys. Rev. Lett. 84, 5304 2000 ; . [Lee05] P. S. K. Lee, M. P. van Exter and J. P. Woerdman, How focused pumping affects type-II spontaneous parametric down-conversion, Phys. Rev. A 72, 033803 2005 ; . [Leu97] D. W. Leung, M. A. Nielsen, I. L. Chuang and Y. Yamamoto, Approximate quantum error correction can lead to better codes, Phys. Rev. A 56, 2567 1997 ; . [Lin06] [Llo98] [Llo99] A. Ling, K. P. Soh, A. Lamas-Linares and C. Kurtsiefer, Experimental polarization state tomography using optimal polarimeters, Phys. Rev. A 74, 022309 2006 ; . S. Lloyd and J.-J. E. Slotine, Analog Quantum Error Correction, Phys. Rev. Lett. 80, 4088 1998 ; . S. Lloyd and S. L. Braunstein, Quantum Computation over Continuous Variables, Phys. Rev. Lett. 82, 1784 1999. Procedure Code Description INJECTION, PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE, UP TO 600, 000 UNITS INJECTION, PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE, UP TO 1, 200, 000 UNITS INJECTION, PENICILLIN G BENZATHINE AND PENICILLIN G PROCAINE, UP TO 2, 400, 000 UNITS INJECTION, PENICILLIN G BENZATHINE, UP TO 600, 000 UNITS INJECTION, PENICILLIN G BENZATHINE, UP TO 1, 200, 000 UNITS INJECTION, PENICILLIN G BENZATHINE, UP TO 2, 400, 000 UNITS INJECTION, BIVALIRUDIN, 1 MG BOTULINUM TOXIN TYPE A, PER UNIT BOTULINUM TOXIN TYPE B, PER 100 UNITS INJECTION, BUPRENORPHINE HYDROCHLORIDE, 0.1 MG INJECTION, BUTORPHANOL TARTRATE, 1 MG INJECTION, EDETATE CALCIUM DISODIUM, UP TO 1000 MG INJECTION, CALCIUM GLUCONATE, PER 10 ML INJECTION, CALCIUM GLYCEROPHOSPHATE AND CALCIUM LACTATE, PER 10 ML INJECTION, CALCITONIN SALMON, UP TO 400 UNITS INJECTION, CALCITRIOL, 0.1 MCG INJECTION, CASPOFUNGIN ACETATE, 5 MG INJECTION, LEUCOVORIN CALCIUM, PER 50MG INJECTION, MEPIVACAINE HYDROCHLORIDE, PER 10 ML INJECTION, CEFAZOLIN SODIUM, 500 MG INJECTION, CEFEPIME HYDROCHLORIDE, 500 MG INJECTION, CEFOXITIN SODIUM, 1 GM INJECTION, CEFTRIAXONE SODIUM, PER 250 MG INJECTION, STERILE CEFUROXIME SODIUM, PER 750 MG INJECTION, CEFOTAXIME SODIUM, PER GM INJECTION, BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, PER 3 MG INJECTION, BETAMETHASONE SODIUM PHOSPHATE, PER 4 MG INJECTION, CAFFEINE CITRATE, 5MG INJECTION, CEFTAZIDIME, PER 500 MG INJECTION, CEFTIZOXIME SODIUM, PER 500 MG INJECTION, CHLORAMPHENICOL SODIUM SUCCINATE, UP TO 1 GM INJECTION, CHORIONIC GONADOTROPIN, PER 1, 000 USP UNITS INJECTION, CLONIDINE HYDROCHLORIDE, 1 MG INJECTION, CIDOFOVIR, 375 MG INJECTION, CILASTATIN SODIUM; IMIPENEM, PER 250 MG INJECTION, CIPROFLOXACIN FOR INTRAVENOUS INFUSION, 200 MG INJECTION, CODEINE PHOSPHATE, PER 30 MG.
Other than the more highly bound ceftriaxone reached a peak rapidly 15 min after the start of dosing ; and were similar to or slightly greater than concentrations in plasma for the duration of the study. Peak lymph temocillin and ticarcillin concentrations were approximately 35% of the concentrations in plasma at 5 min after dosing, whereas the ratio of peak concentrations in lymph to 5-min concentrations in plasma of amoxicillin and clavulanic acid were higher at 52 and 55%, respectively. Concentrations of ceftriaxone in lymph reached a peak later, at approximately 1 to 1.5 h after the start of dosing, and were generally lower than concentrations in plasma at all times. Peak concentrations of ceftriaxone in lymph were approximately 39% of the corresponding 5-min concentrations in plasma, and concentrations in lymph at 15 min were considerably lower, only 22% of those in plasma at 5 min. AUCs and half-lives in plasma and lymph and the percent penetration AUC in lymph AUC in plasma 100 ; are shown in Tables 4 and 5. The half-life in plasma was generally similar to the half-life in lymph for all the compounds tested. The percent penetration of amoxicillin, clavulanic acid, and temocillin into lymph was 89%. Ticarcillin penetrated to a slightly lesser degree 76.0% ; , and ceftriaxone showed the lowest penetration figure 67.3% ; . Correction of the concentrations measured in plasma and lymph for the extent of protein.
Included on the PDL. Dr. Avery moved to add Zoloft on the PDL, because of its frequent use in children and the nursing home population. Dr. Wandstrat indicated that savings would be significantly impacted with the addition of Zoloft. The motion was seconded to include Zoloft, votes were taken, and the motion was carried. The list was accepted as follows. A high dose of penicillin or ceftriaxone is usually required in the late stages of the disease to treat the infection and celestone. REPORT ORG06 * * MINNESOTA DATA MANAGEMENT * VERIFICATION OF THE 2005-06 MINNESOTA DEPARTMENT * ED-00908-17 * * DEPT. OF 1500 HIGHWAY 36 W. * OF EDUCATION DATABASE * DUE 6 30 06 * * EDUCATION ROSEVILLE MN 55113 * * SEQUENCE: NUMERIC * * TYP-DST-SCH DISTRICT SCHOOL NAME SUPERINTENDENT DST SCH PHONE DST SCH FAX LOCATION STREET ADDRESS CITY COUNTY STATE ZIP MAILING ADDRESS CITY MAGNET STATE ZIP 6-8 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-639 K-6 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-640 K-12 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-641 4-8 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-642 K-6 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-643 1-6 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-644 9-12 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-647 K-8 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-648 9-12 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-650 9-12 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-651 1-6 LOCATION ADDRESS: MAILING ADDRESS: 06-0287-653 K-6 LOCATION ADDRESS: MAILING ADDRESS: 45 281 PLYMOUTH MIDDLE TS 10011 36TH AVE. N. 4148 WINNETKA AVE. N. 271 POND EL TS 9600 3RD AVE. 4571 W. 102ND ST. 281 ROBBINSDALE WINGS ALC 4139 REGENT AVE. N. 4148 WINNETKA AVE. N. 281 SANDBURG MIDDLE TS 2400 SANDBURG LANE 4148 WINNETKA AVE. N. 281 SONNESYN EL TS 3421 BOONE AVE. N. 3421 BOONE AVE. N. 281 SUNNY HOLLOW EL TS 8808 MEDICINE LAKE ROAD 4148 WINNETKA AVE. N. PRAIRIE CTR. ALC 9955 W. 69TH ST. 9955 W. 69TH ST. 279 WEAVER LAKE EL TS 15900 WEAVER LAKE RD. 11200 93RD AVE. N. 281 WINNETKA LEARNING CTR. ALC 7940 55TH AVE. N. 7940 55TH AVE. N. 281 HIGHVIEW ALTERNATIVE PROGRAM 5400 CORVALLIS AVENUE NORTH 5400 CORVALLIS AVENUE NORTH 279 GARDEN CITY EL TS 3501 65TH AVE. N. 11200 93RD AVE. N. 279 BIRCH GROVE EL. TS. 4690 BROOKDALE DR. N. 11200 93RD AVE. N. CLAIRE VINCENT PLYMOUTH NEW HOPE CONNIE DOVE BLOOMINGTON BLOOMINGTON CLAIRE VINCENT ROBBINSDALE NEW HOPE CLAIRE VINCENT GOLDEN VALLEY NEW HOPE CLAIRE VINCENT NEW HOPE NEW HOPE CLAIRE VINCENT NEW HOPE NEW HOPE JIM SNAVELY EDEN PRAIRIE EDEN PRAIRIE DOLLY BINA MAPLE GROVE MAPLE GROVE NANCY PALMER NEW HOPE NEW HOPE CHRIS ROWE-BARTEL CRYSTAL CRYSTAL DOLLY BINA BROOKLYN CENTER MAPLE GROVE DOLLY BINA BROOKLYN PARK MAPLE GROVE 27 NO 27 763-504-8074 763-504-8970 MN 55441-2491 MN 55427 - MN 55420- MN 55437- 763-504-8074 763-504-8972 MN 55422- MN 55427- 763-504-8074 763-504-8970 MN 55427-3664 MN 55427- 763-504-8074 763-504-8972 MN 55427-1899 MN 55427- 763-504-8074 763-504-8972 MN 55427- MN 55427- 952-941-7860 952-941-7848 MN 55344- MN 55344- 763-391-7176 763-391-7076 MN 55369-9566 MN 55369- 763-504-8300 763-504-8309 MN 55428- MN 55428- 763-504-8700 763-504-8709 MN 55429- MN 55429- 763-391-7176 763-391-7076 MN 55429-2299 MN 55369- 763-391-7176 763-391-7076 MN 55443-2699 MN 55369- GRD-LVL CLASSIFICATION.

[1] "sum" "sum" "ratio" # Use matplot to make a graph matplot t st[3 1: 11] # Use matplot to make nice a graph matplot t st[3 1: 11] ; , log "y", type "l", lwd 4, lty 1 ; # 8: # Modelling by a smooth function # system.time + thx - Lexis entry cal.yr injecdat ; , + exit cal.yr exitdat ; , + fail !is.na cause ; , # & is.na liverdat ; , + origin cal.yr injecdat ; , + breaks seq 1, 100, 0.5 ; , + include list id, contrast, volume, birthdat, sex ; , + data thoro ; + ; [1] 4.73 0.14 5.67 NA NA str thx ; data ame': 100532 obs. of 10 variables: $ Expand : num 1 Entry : num 1940 1941 . $ Exit : num 1940 1941 . $ Fail : num 0 0 0 Time : num 1 1.5 2 . $ id num 1 contrast: num 1 volume : num 22 birthdat: Class 'Date' num [1: 100532] -19501 -19501 -19501 -19501 -19501 . $ sex : num 2 library splines ; # knots, boundary knots and timepoints for prediction kn - c 4, 8, seq 10, 40, 10 bk - c 1, 50 ; seq 1, 50, 0.2 ; # The model with natural splines and interaction system.time + m1 - glm Fail ~ -1 + factor contrast ; : ns Time + 0.25, knots kn, Bo bk, intercept TRUE ; + + offset log Exit-Entry ; 1000 , + family poisson, data thx ; + ; [1] 18.36 1.98 26.48 NA NA plt "Tht-RR" ; par mar c 3, 1, ; , mgp c 3, 1, 0 ; 1.6, las 1 ; # Contrast matrix for the rates CM -ns tp, knots kn, Bo bk, intercept TRUE ; # Extract the rates for each group lmort1 - ci.lin m1, ctr.mat CM, subset "1: ns", E T ; [, 5: 7] lmort2 - ci.lin m1, ctr.mat CM, subset "2: ns", E T ; [, 5: 7] matplot tp, cbind lmort1, lmort2 ; , type "l", ylim c 5, 200 ; , + log "y", lty 1, lwd rep c 4, 1, ; , 2 ; , col rep c "red", "blue" ; , each 3 ; , + xlab "Time since angiograpy years ; ", + ylab "Mortality rate per 1000 PY" ; # ci.lin can also be used to extract the rate ratio: rr - ci.lin m1, ctr.mat cbind CM, -CM ; , subset c "1: ns", "2: ns" ; , E T ; [, 5: reference level for the RR 1 on the graph matlines tp, rr * rr , type "l", lwd c 4, 1, ; , col "black", lty 1 ; abline h rr ; axis side 4, at rr * x - 10, , labels x ; mtext "Rate ratio", side 4, line 3 1.6, las 0 ; # Further split of data for SMR-calculations: # Not very many new recoreds, but two variables agr and per # are created for use in matching up with the mortality data th1x - Lexis entry Entry, exit Exit, fail Fail, + origin list agr cal.yr birthdat ; , per 1900 ; , + breaks list agr seq 0, 120, 5 ; , per seq 38, 93, 5 , + # The age need to extend 120 because one person has lived to + # be 110, and Lexis will crash of any input record is entirely + # outside the range of any the breaks lists + data thx, + include list id, contrast, volume, birthdat, Time, sex str th1x ; data ame': 120284 obs. of 12 variables: $ Expand : num 1 2 3 Entry : num 1940 1941 . $ Exit : num 1940 1941 . $ Fail : num 0 0 0 agr : num 20 per : num 38 num 1 contrast: num 1 volume : num 22 birthdat: Class 'Date' num [1: 120284] -19501 -19501 -19501 -19501 -19501 . $ Time : num 1 1.5 2 . $ sex : num 2 Now get the population data.
Ceftriaxone is often used to treat secondary lyme disease and is given for a month when heart or central nervous system complications arise!